长效注射卡博特韦在低风险HIV未感染人群中的安全性、耐受性与药代动力学:HPTN 077 2a期随机对照试验
HPTN 077是一项双盲、安慰剂对照2a期试验,在巴西、马拉维、南非和美国8个中心纳入低HIV风险的健康成人,随机接受口服卡博特韦或安慰剂4周后序贯进入注射阶段。主要结局为安全性和耐受性,次要结局包括药代动力学。结果显示长效卡博特韦注射总体耐受良好,注射部位反应常见但极少导致停药,600 mg每8周方案在男女中均达到预设药代动力学目标。
要点
- 长效卡博特韦注射部位反应常见(队列1为92%,队列2为88%),但多为轻至中度,仅1例导致停药。
- 队列2(600 mg每8周)中至少95%参与者维持CAB谷浓度高于PA-IC90,80%高于4倍PA-IC90。
- 研究期间发生1例HIV感染,发生于末次注射后48周,当时及此前12周血浆中均未检出CAB。
核心结论
- 长效卡博特韦在所用药和给药间隔下耐受良好,注射部位反应常见但极少导致停药,600 mg每8周方案在男女中均达到预设药代动力学目标。
研究设计与样本
- HPTN 077为双盲、安慰剂对照2a期试验,在巴西、马拉维、南非和美国8个中心开展。
- 健康低HIV风险成人年龄18-65岁按3:1随机接受卡博特韦或安慰剂,先口服4周再进入注射阶段。
- 队列1接受800 mg每12周肌注3次,队列2接受600 mg肌注5次(前2次间隔4周,其余间隔8周)。
- 研究筛查443人,队列1入组110人,队列2入组89人;主要分析涵盖第5至41周(注射阶段)。
主要发现
- 接受至少1次长效卡博特韦注射者中,队列1的80%和队列2的92%完成全部注射,完成率与安慰剂组无差异。
- 注射部位反应常见:队列1为92%、队列2为88%的接受长效卡博特韦者报告任何注射部位反应,多为1-2级。
- 仅1例注射部位反应导致停药;2例3级注射部位反应(每队列1例)未导致停药。
- 7例新发性传播感染诊断于6名参与者;1例HIV感染发生于末次注射后48周,当时及此前12周血浆CAB均未检出。
- 队列2中至少95%参与者维持CAB谷浓度高于PA-IC90,80%高于4倍PA-IC90;队列1未始终达到该预设目标。
关键数值与推荐
- 队列1:CAB LA 800 mg肌注,每12周1次,共3次。
- 队列2:CAB LA 600 mg肌注,共5次,前2次间隔4周,其余间隔8周。
- 口服阶段:每日1片口服片(CAB或安慰剂)共4周。
- 药代动力学预设目标:至少95%参与者CAB谷浓度高于PA-IC90,80%高于4倍PA-IC90。
临床怎么用
- 长效卡博特韦注射方案在低风险人群中耐受良好,注射部位反应多为轻中度,因反应停药少见。
- 600 mg每8周方案在男女中均达到预设药代动力学目标,支持进一步开展HIV治疗和预防的疗效研究。
局限性
- 样本量有限。
- 注射疗程较短。
- 研究人群为低HIV风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States. METHODS AND FINDINGS: HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population. CONCLUSIONS: In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress. TRIAL REGISTRATION: ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800.
引用
- Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018. PMID: 30408115. doi:10.1371/journal.pmed.1002690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。